GlassScriptPhysician profile
Gaurav Chand
NPI 1346655586
$14,080.91
in general payments reported to CMS, 2019-2025
41 companies · $3,415 in 2025
The $3,415 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $531 · 2021: $2,257 · 2022: $1,964 · 2023: $2,550 · 2024: $3,019 · 2025: $3,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,839 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,839.41 |
| Education | $144.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,850.83 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,469.49 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,137.73 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,041.84 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $811.25 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $495.60 | 2020-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $454.25 | 2022-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $393.83 | 2020-2025 | Givlaari |
| Pfizer INC. | $333.31 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $307.21 | 2025 | Zenpep |
| Qol Medical, LLC | $304.08 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $261.47 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $235.42 | 2020-2023 | Ocaliva |
| Celgene Corporation | $209.01 | 2021-2024 | Zeposia |
| Genzyme Corporation | $157.02 | 2022-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gaurav Chand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.